Publications by authors named "Prabhakar Viswanathan"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

30,891

Total Likes

1,661

Extended Reach

3,811,660

Social Features

248
F
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.
Jawad H Butt, Pardeep S Jhund, Alasdair D Henderson, Brian L Claggett, Akshay S Desai, Prabhakar Viswanathan

Eur J Heart Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF.
Toru Kondo, Pardeep S Jhund, Alasdair D Henderson, Brian L Claggett, Akshay S Desai, Prabhakar Viswanathan

Eur J Heart Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.
Jawad H Butt, Pardeep S Jhund, Alasdair D Henderson, Brian L Claggett, Akshay S Desai, Prabhakar Viswanathan

Eur J Heart Fail· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.
Maria A Pabon, Orly Vardeny, Muthiah Vaduganathan, Akshay S Desai, Brian L Claggett, Prabhakar Viswanathan

JAMA Cardiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease.
John W Ostrominski, Brian L Claggett, Zi Michael Miao, Gerasimos Filippatos, Akshay S Desai, Prabhakar Viswanathan

Diabetes Care· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.
Misato Chimura, Mingming Yang, Alasdair D Henderson, Pardeep S Jhund, Kieran F Docherty, Prabhakar Viswanathan

Eur J Heart Fail· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
Muthiah Vaduganathan, Brian L Claggett, Akshay S Desai, Pardeep S Jhund, Carolyn S P Lam, Prabhakar Viswanathan

JAMA Cardiol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.
Jawad H Butt, Pardeep S Jhund, Alasdair D Henderson, Brian L Claggett, Akshay S Desai, Prabhakar Viswanathan

Lancet Diabetes Endocrinol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
Jonathan W Cunningham, Safia Chatur, Brian L Claggett, Muthiah Vaduganathan, Akshay S Desai, Prabhakar Viswanathan

JAMA Cardiol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.
Muthiah Vaduganathan, Brian L Claggett, Ian J Kulac, Zi Michael Miao, Akshay S Desai, Prabhakar Viswanathan

Circulation· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial.
Kieran F Docherty, Alasdair D Henderson, Pardeep S Jhund, Brian L Claggett, Akshay S Desai, Prabhakar Viswanathan

Circulation· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial.
Akshay S Desai, Muthiah Vaduganathan, Brian L Claggett, Ian J Kulac, Pardeep S Jhund, Prabhakar Viswanathan

J Am Coll Cardiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.
Mingming Yang, Alasdair D Henderson, Atefeh Talebi, John J Atherton, Chern-En Chiang, Prabhakar Viswanathan

J Am Coll Cardiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Orly Vardeny, Muthiah Vaduganathan, Brian L Claggett, Akshay S Desai, Pardeep S Jhund, Prabhakar Viswanathan

JAMA Cardiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
Misato Chimura, Xiaowen Wang, Pardeep S Jhund, Alasdair D Henderson, Brian L Claggett, Prabhakar Viswanathan

JAMA Cardiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.
Jawad H Butt, Alasdair D Henderson, Pardeep S Jhund, Brian L Claggett, Akshay S Desai, Prabhakar Viswanathan

J Am Coll Cardiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.
Shingo Matsumoto, Pardeep S Jhund, Alasdair D Henderson, Johann Bauersachs, Brian L Claggett, Prabhakar Viswanathan

J Am Coll Cardiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.
Muthiah Vaduganathan, Gerasimos Filippatos, Brian L Claggett, Akshay S Desai, Pardeep S Jhund, Prabhakar Viswanathan

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.
Muthiah Vaduganathan, Gerasimos Filippatos, Brian L Claggett, Akshay S Desai, Pardeep S Jhund, Prabhakar Viswanathan

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gamified Behavioral Science Intervention to Enhance Trial Enrollment: An Embedded Study Within the FINEARTS-HF Trial.
Ankeet S Bhatt, Safia Chatur, Brian L Claggett, James Lay-Flurrie, Prabhakar Viswanathan

JACC Heart Fail· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF.
Misato Chimura, Mark C Petrie, Morten Schou, Felipe A Martinez, Alasdair D Henderson, Prabhakar Viswanathan

Circ Heart Fail· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure.
John W Ostrominski, Rahul Aggarwal, Brian L Claggett, Ian J Kulac, Akshay S Desai, Prabhakar Viswanathan

J Card Fail· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis.
John W Ostrominski, Brian L Claggett, Zi Michael Miao, Finnian R Mc Causland, Inder S Anand, Prabhakar Viswanathan

J Am Coll Cardiol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial.
Muthiah Vaduganathan, Brian L Claggett, Carolyn S P Lam, Bertram Pitt, Michele Senni, Prabhakar Viswanathan

Eur J Heart Fail· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis